TCBIO — Stock Film
STOCK FILMSCENE 1/10TCBIO · $19.71
Stock Expert AI presents
TCBIO
Texas Capital Bancshares, Inc
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
Texas Capital Bancshares, Inc. What it actually does.

Provides commercial banking services to businesses. Offers consumer banking products, including checking and savings accounts. Now — the numbers.

on the stock market since 2021
1,785 employees
$4.3B market value
Revenue last year:
$2B
The net profit left over:
$330.2M
Out of every $100 of revenue, $17 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 17%

This is an established company with proven profits.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 19% a year over the last 4 years. Every year shown ended in profit.

$987.1M
2021
2022
2023
2024
$2B
2025
THE PRICE TAG
MARKET VALUE / ANNUAL PROFIT
12.9×

The market pays 12.9× for every dollar of annual profit — cheap, which is either an opportunity or a warning.

Against companies in its own sector, it looks cheaper than 86% of them.

No analyst target is on record for this company.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
77
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
67
strong

For a bank, strength is measured by capital buffers and reserves — not cash minus debt.

VALUATION
86
very strong

The price looks reasonable next to what the company earns.

GROWTH
98
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
20
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 27% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
A fat but narrowing margin

The net profit margin is 17% — still a thick cushion, though costs have been eating into it lately.

2
THE BRIGHT SIDE · 2/3
Sales keep climbing

Over the last 4 years, sales grew about 19% a year on average.

3
THE BRIGHT SIDE · 3/3
Executives are buying their own stock

Over the last 12 months, company executives reported 74 buys and 64 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 20/100. For a turnaround signal, the stock first needs to close the gap with the market.

2
THE RISKS · 2/2
Thin trading in the shares

Getting in and out without moving the price could prove difficult.

FINALE · THE GRADE
A+
82 / 100 · MoonshotScore

On our five-subject report card, TCBIO sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: TCBIO is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →

Not covered, because the filings we hold do not carry it: the revenue breakdown.

This was a film — not investment advice.
Data: FMP & company filings
Sep 11, 2026 · stockexpertai.com · Stock Film